{"title":"Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy.","authors":"Yingfeng Zhang, Yuanyuan He, Chenyi Dai, Zhengyang Zhou, Yudi Miao, Zixin Zhao, Qi Lei, Cheng Li, Chengyan Wang, Hongkui Deng","doi":"10.1016/j.crmeth.2024.100843","DOIUrl":null,"url":null,"abstract":"<p><p>Dual-attribute immune cells possess advantageous features of cytotoxic T cells and natural killer (NK) cells and hold promise for advancing immunotherapy. Dual-attribute cell types such as invariant natural killer T cells, induced T-to-NK cells, and cytokine-induced killer cells have demonstrated efficacy and safety in preclinical and clinical studies. However, their limited availability hinders their widespread application. Human pluripotent stem cells (hPSCs) offer an ideal source. Here, we generate dual-attribute induced T-NK (iTNK) cells from hPSCs, expressing markers of both cytotoxic T and NK cells. Single-cell RNA and T cell receptor (TCR) sequencing analyses reveal that iTNK cells expressed signature genes associated with both NK and T cells and displayed a diverse TCR repertoire. iTNK cells release cytotoxic mediators, exert cytotoxicity against diverse tumor cell lines, and inhibit tumor growth in vivo. By harnessing adaptive and innate immune responses, hPSC-derived iTNK cells offer promising strategies for cancer immunotherapy.</p>","PeriodicalId":29773,"journal":{"name":"Cell Reports Methods","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440056/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Reports Methods","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.crmeth.2024.100843","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
Dual-attribute immune cells possess advantageous features of cytotoxic T cells and natural killer (NK) cells and hold promise for advancing immunotherapy. Dual-attribute cell types such as invariant natural killer T cells, induced T-to-NK cells, and cytokine-induced killer cells have demonstrated efficacy and safety in preclinical and clinical studies. However, their limited availability hinders their widespread application. Human pluripotent stem cells (hPSCs) offer an ideal source. Here, we generate dual-attribute induced T-NK (iTNK) cells from hPSCs, expressing markers of both cytotoxic T and NK cells. Single-cell RNA and T cell receptor (TCR) sequencing analyses reveal that iTNK cells expressed signature genes associated with both NK and T cells and displayed a diverse TCR repertoire. iTNK cells release cytotoxic mediators, exert cytotoxicity against diverse tumor cell lines, and inhibit tumor growth in vivo. By harnessing adaptive and innate immune responses, hPSC-derived iTNK cells offer promising strategies for cancer immunotherapy.
双属性免疫细胞具有细胞毒性 T 细胞和自然杀伤(NK)细胞的优势特征,有望推动免疫疗法的发展。在临床前研究和临床研究中,不变自然杀伤 T 细胞、诱导 T 转 NK 细胞和细胞因子诱导杀伤细胞等双属性细胞类型已证明了其有效性和安全性。然而,这些细胞的有限可用性阻碍了它们的广泛应用。人类多能干细胞(hPSCs)提供了一个理想的来源。在这里,我们从 hPSCs 中生成了双属性诱导 T-NK (iTNK)细胞,同时表达细胞毒性 T 细胞和 NK 细胞的标记。单细胞 RNA 和 T 细胞受体(TCR)测序分析表明,iTNK 细胞表达了与 NK 和 T 细胞相关的特征基因,并显示了多样化的 TCR 反应谱系。iTNK 细胞释放细胞毒性介质,对多种肿瘤细胞株发挥细胞毒性,并抑制体内肿瘤生长。通过利用适应性和先天性免疫反应,hPSC衍生的iTNK细胞为癌症免疫疗法提供了前景广阔的策略。